ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Sana Biotechnology unveils mega funding round

by Lisa M. Jarvis
June 26, 2020 | APPEARED IN VOLUME 98, ISSUE 25

 

Engineered cell therapy–focused Sana Biotechnology has completed its initial funding round, bringing in a whopping $700 million. The funds will be used to develop preclinical drug candidates, establish manufacturing capabilities, and expand the firm’s technology platform. Sana was launched in 2019 by executives from Juno Therapeutics, a cell therapy company bought by Celgene in 2018. Sana has grown to more than 200 employees working toward its ambitions of repairing or controlling any gene and replacing any cell.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment